Skyler Brands claims next generation anti-aging launch

03-Jun-2015 - Last updated on 04-Jun-2015 at 15:04 GMT

Skyler Brand Ventures, which calls itself an R&D incubator for the cosmetics industry, says that its ERASA XEP-30 combines some of the most cutting edge science of any product launched in the anti-aging facial care category.

Skyler was founded by former chief scientist and head for applied research at Estée Lauder, Jules Zecchio, who for over 20 years created some of the best-selling product launches for the business.

The research and development team at Skyler includes some of the leading names in formulation, such as Dr. Konnie Lahanas, formerly of Limited Brands, whose combined talents have been focused on creating the business’s first portfolio company, BioMimetic Laboratories.

Biomimetics raise the bar

As the name suggests, the division is focused on utilizing the most cutting edge biotechnology available to create anti-aging skin care products with an efficacy that is said to set a new industry standard.

While Biomimetics Laboratories has been three years in the making, ERASA EXP-30 is only its first product launch and came about thanks to a collaboration with Activen, the cosmetics affiliate of Swiss biotechnology company Atheris Laboratories.

The resulting global R&D partnership has produced a skin care product that is said to be a superior anti-aging skin concentrate formulated on the back of the patent rights for Activen’s benchmark neuropeptides, alongside a patent-pending delivery system that ensures deep skin penetration.

The results

The company’s development team says that the end result is a product that helps to erase wrinkles, including deep frown and expression lines – while restoring elasticity and skin tone.

The company says that independent clinical lab tests have shown results “never-before-seen” in a topical, including up to 92% wrinkle reduction, 83% pore reduction, and 37% age spot reduction.

"The outstanding clinical results are a validation of the research structure and the highly productive collaboration of Skyler and its research affiliates, something that is extremely pleasing to our consumers and our investors alike,” said Zecchio.

“We look forward to setting the ultimate standard in the industry for product efficacy and clinical testing in all Skyler companies and products".